479 related articles for article (PubMed ID: 19690886)
1. LAPTM4B-35 overexpression is a risk factor for tumor recurrence and poor prognosis in hepatocellular carcinoma.
Yang H; Xiong FX; Lin M; Yang Y; Nie X; Zhou RL
J Cancer Res Clin Oncol; 2010 Feb; 136(2):275-81. PubMed ID: 19690886
[TBL] [Abstract][Full Text] [Related]
2. Combined lysosomal protein transmembrane 4 beta-35 and argininosuccinate synthetase expression predicts clinical outcome in hepatocellular carcinoma patients.
Yang H; Lin M; Xiong F; Yang Y; Nie X; McNutt MA; Zhou R
Surg Today; 2011 Jun; 41(6):810-7. PubMed ID: 21626328
[TBL] [Abstract][Full Text] [Related]
3. LAPTM4B-35 is a novel prognostic factor of hepatocellular carcinoma.
Yang H; Xiong F; Qi R; Liu Z; Lin M; Rui J; Su J; Zhou R
J Surg Oncol; 2010 Apr; 101(5):363-9. PubMed ID: 20358632
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of matrix metalloproteinase-1/ proteinase-activated receptor-1 signaling axis in hepatocellular carcinoma.
Liao M; Tong P; Zhao J; Zhang Y; Li Z; Wang J; Feng X; Hu M; Pan Y
Pathol Oncol Res; 2012 Apr; 18(2):397-403. PubMed ID: 21909684
[TBL] [Abstract][Full Text] [Related]
5. Neuron-glial antigen 2 overexpression in hepatocellular carcinoma predicts poor prognosis.
Lu LL; Sun J; Lai JJ; Jiang Y; Bai LH; Zhang LD
World J Gastroenterol; 2015 Jun; 21(21):6649-59. PubMed ID: 26074703
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of LAPTM4B: an independent prognostic marker in breast cancer.
Xiao M; Jia S; Wang H; Wang J; Huang Y; Li Z
J Cancer Res Clin Oncol; 2013 Apr; 139(4):661-7. PubMed ID: 23292099
[TBL] [Abstract][Full Text] [Related]
7. High level of intercellular adhesion molecule-1 affects prognosis of patients with hepatocellular carcinoma.
Zhu PP; Yuan SG; Liao Y; Qin LL; Liao WJ
World J Gastroenterol; 2015 Jun; 21(23):7254-63. PubMed ID: 26109813
[TBL] [Abstract][Full Text] [Related]
8. Predictive significance of combined LAPTM4B and VEGF expression in patients with cervical cancer.
Meng F; Tan S; Liu T; Song H; Lou G
Tumour Biol; 2016 Apr; 37(4):4849-55. PubMed ID: 26526574
[TBL] [Abstract][Full Text] [Related]
9. Overexpressed LAPTM4B-35 is a risk factor for cancer recurrence and poor prognosis in non-small-cell lung cancer.
Kong F; Gao F; Chen J; Sun Y; Zhang Y; Liu H; Li X; Yang P; Zheng R; Liu G; Jia Y
Oncotarget; 2016 Aug; 7(35):56193-56199. PubMed ID: 27486880
[TBL] [Abstract][Full Text] [Related]
10. LAPTM4B allele *2 is a marker of poor prognosis following hepatic tumor resection for hepatocellular carcinoma.
Yang H; Zhai G; Ji X; Xiong F; Su J; McNutt MA
PLoS One; 2012; 7(4):e34984. PubMed ID: 22509374
[TBL] [Abstract][Full Text] [Related]
11. Low levels of glycoprotein 96 indicate a worse prognosis in early-stage hepatocellular carcinoma patients after hepatectomy.
Ji F; Zhang Y; Zhu ZB; Guo Y; Shen SL; Cao QH; Li SQ; Peng BG; Liang LJ; Hua YP
Hum Pathol; 2019 Apr; 86():193-202. PubMed ID: 30529751
[TBL] [Abstract][Full Text] [Related]
12. [A new prognostic score system of hepatocellular carcinoma following hepatectomy].
Wang YK; Bi XY; Li ZY; Zhao H; Zhao JJ; Zhou JG; Huang Z; Zhang YF; Li MX; Chen X; Wu XL; Mao R; Hu XH; Hu HJ; Liu JM; Cai JQ
Zhonghua Zhong Liu Za Zhi; 2017 Dec; 39(12):903-909. PubMed ID: 29262506
[No Abstract] [Full Text] [Related]
13. C-reactive protein may be a prognostic factor in hepatocellular carcinoma with malignant portal vein invasion.
Kim JM; Kwon CH; Joh JW; Ko JS; Park JB; Lee JH; Kim SJ; Paik SW; Park CK
World J Surg Oncol; 2013 Apr; 11():92. PubMed ID: 23618082
[TBL] [Abstract][Full Text] [Related]
14. Lysosomal-associated protein transmembrane 4 Beta-35 overexpression is a novel independent prognostic marker for gastric carcinoma.
Liu L; Xu X; Jing L; Zhou G; Cao Z; Han Y; Zhou R
PLoS One; 2015; 10(2):e0118026. PubMed ID: 25689860
[TBL] [Abstract][Full Text] [Related]
15. Post-hepatectomy survival in advanced hepatocellular carcinoma with portal vein tumor thrombosis.
Yamamoto Y; Ikoma H; Morimura R; Shoda K; Konishi H; Murayama Y; Komatsu S; Shiozaki A; Kuriu Y; Kubota T; Nakanishi M; Ichikawa D; Fujiwara H; Okamoto K; Sakakura C; Ochiai T; Otsuji E
World J Gastroenterol; 2015 Jan; 21(1):246-53. PubMed ID: 25574098
[TBL] [Abstract][Full Text] [Related]
16. Low expression of organic anion-transporting polypeptide 1B3 predicts a poor prognosis in hepatocellular carcinoma.
Chen S; Li K; Jiang J; Wang X; Chai Y; Zhang C; Deng Q; Shuai L; Feng K; Ma K; Zhang L
World J Surg Oncol; 2020 Jun; 18(1):127. PubMed ID: 32534581
[TBL] [Abstract][Full Text] [Related]
17. Fidgetin as a potential prognostic biomarker for hepatocellular carcinoma.
Zhou B; Wang J; Gao J; Xie J; Chen Y
Int J Med Sci; 2020; 17(17):2888-2894. PubMed ID: 33162817
[No Abstract] [Full Text] [Related]
18. Expression of fibroblast growth factor 19 is associated with recurrence and poor prognosis of hepatocellular carcinoma.
Hyeon J; Ahn S; Lee JJ; Song DH; Park CK
Dig Dis Sci; 2013 Jul; 58(7):1916-22. PubMed ID: 23456506
[TBL] [Abstract][Full Text] [Related]
19. A novel prognostic biomarker SPC24 up-regulated in hepatocellular carcinoma.
Zhu P; Jin J; Liao Y; Li J; Yu XZ; Liao W; He S
Oncotarget; 2015 Dec; 6(38):41383-97. PubMed ID: 26515591
[TBL] [Abstract][Full Text] [Related]
20. High expression of CCL20 is associated with poor prognosis in patients with hepatocellular carcinoma after curative resection.
Ding X; Wang K; Wang H; Zhang G; Liu Y; Yang Q; Chen W; Hu S
J Gastrointest Surg; 2012 Apr; 16(4):828-36. PubMed ID: 22072303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
